跳至主要内容
临床试验/NCT04228848
NCT04228848已完成不适用

Examination of New Triple Hop Test Assessment Tool for Adults and Adolescents, Healthy and After Anterior Cruciate Ligament Injury

University of Haifa1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2020年7月26日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
60
试验地点
1
主要终点
New triple hop test score

研究概览

简要总结

This study will develop a new jump assessment tool for the Triple Hop Test, and will test its reliability on adolescent and adult, healthy and post- anterior cruciate ligament (ACL) population.

Creating a new assessment test for a jump test that incorporates the known movement components that are important after an ACL injury can improve patient evaluation, decision for return to sport activity and injury prevention.

详细描述

Study population- Adults, women and men aged 20-45, boys and girls aged 12-15. uninjured population: non symptomatic subjects, without major injury in their history. Injured population: ACL injured subjects, 9-12 month after beginning of treatment/surgery.

Stages of study:

stage 1- The investigators will create a new high-quality literature-based assessment test for the triple hop test (NTHT). The test will have 10 sections, its score ranges from 0 to 14 points and a high score means poor performance.

Stage 2- Performing reliability tests between and within the testers for NTHT. The tests will be done with the help of video photography of NTHT.

Stage 3- Performing NTHT and THT tests on healthy adult and adolescent subjects and on ACL adult and adolescent subjects, assessing the NTHT by watching video performance.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Screening
盲法
None

入排标准

年龄范围
12 Years 至 45 Years(Child, Adult)
性别
All
接受健康志愿者
是

入选标准

  • •uninjured population:
  • •non symptomatic subjects
  • •without major injury in their history.
  • •Inclusion Criteria injured population:
  • •ACL injured subjects
  • •9-12 month after beginning of treatment/surgery.

排除标准

  • •uninjured population:
  • •acute pain
  • •knee instability symptoms
  • •history of lower leg injury
  • •unable to jump on one leg
  • •knee ligament injury.
  • •Exclusion Criteria Injured population:
  • •late in rehabilitation program
  • •unable to jump or run
  • •instability symptoms.

研究组 & 干预措施

Healthy adult

Active Comparator

Each participants will be asked to perform triple hop test on a straight line and to stand stable at the end of the jump. Two jumps will be performed on each leg, with 1 minute rest between them. The jumps will be recorded via video. Legs muscle strength will be assessed using hand held dynamometer

干预措施: new triple hop test (Other)

ACL adult

Experimental

Each participants will be asked to perform triple hop test on a straight line and to stand stable at the end of the jump. Two jumps will be performed on each leg, with 1 minute rest between them. The jumps will be recorded via video. Legs muscle strength will be assessed using hand held dynamometer

干预措施: new triple hop test (Other)

Healthy adolescent

Active Comparator

Each participants will be asked to perform triple hop test on a straight line and to stand stable at the end of the jump. Two jumps will be performed on each leg, with 1 minute rest between them. The jumps will be recorded via video. Legs muscle strength will be assessed using hand held dynamometer

干预措施: new triple hop test (Other)

ACL adolescent

Experimental

Each participants will be asked to perform triple hop test on a straight line and to stand stable at the end of the jump. Two jumps will be performed on each leg, with 1 minute rest between them. The jumps will be recorded via video.Legs muscle strength will be assessed using hand held dynamometer

干预措施: new triple hop test (Other)

结局指标

主要结局

New triple hop test score

时间窗: baseline

the score ranges between 0-14. lower score represent better jumping quality.

triple hop test

时间窗: baseline

measurement of jumping distance(in cm) and symmetry between legs

muscle strength

时间窗: baseline

muscle strength in Newton, assessed by an hand held dynamometer.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Gali Dar

Head of department of Physical therapy

University of Haifa

研究点 (1)

Loading locations...

相似试验

进行中(未招募)
1 期
Estudio de fase III para evaluar la eficacia y la seguridad de docetaxel y prednisona con o sin lenalidomida en pacientes con cáncer de próstata resistente a la castración (CPRC).A PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DOCETAXEL AND PREDNISONE WITH OR WITHOUT LENALIDOMIDE IN SUBJECTS WITH CASTRATE-RESISTANT PROSTATE CANCERPacientes con cáncer de próstata metastásico sin experiencia de quimioterapia y con elevación documentada del antígeno prostático específico (PSA) o enfermedad progresiva (EP) documentada después de tratamiento hormonal.Chemo-naïve metastatic prostate cancer subjects with documented rising Prostate Specific Antigen (PSA) or documented Progressive Disease (PD) following hormonal therapyMedDRA version: 12.0Level: PTClassification code 10036909Term: Prostate cancer metastatic
EUCTR2008-007969-23-ESCelgene Corporation1,015
进行中(未招募)
1 期
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non-G551D CFTR MutatioMedDRA version: 18.0 Level: PT Classification code 10011762 Term: Cystic fibrosis System Organ Class: 10010331 - Congenital, familial and genetic disorderscystic fibrosis
EUCTR2012-000389-39-GBVertex Pharmaceuticals Incorporated125
进行中(未招募)
1 期
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non-G551D CFTR MutatioMedDRA version: 17.0Level: PTClassification code 10011762Term: Cystic fibrosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersCystic Fibrosis
EUCTR2012-000389-39-BEVertex Pharmaceuticals Incorporated120
进行中(未招募)
1 期
Ensayo pivotal de fase III para determinar la eficacia y la seguridad del comprimido bucodispersable de vardenafilo comparado con placebo en el tratamiento de hombres con disfunción eréctil (DE) – ensayo multicéntrico, aleatorizado, doble ciego y de dosis fija – POTENT I Pivotal phase III trial to investigate the efficacy and safety of an Orodispersible Tablet vardenafil versus placebo in the treatment of men with Erectile dysfunction (ED) - a fixed-dose, double-blind, raNdomized multi-center Trial - POTENT I - POTENT IDisfunción eréctil (DE) Erectile Dysfunction (ED)MedDRA version: 9.1 Level: LLT Classification code 10061461 Term: Erectile dysfunction
EUCTR2008-000536-40-ESBayer HealthCare AG
进行中(未招募)
1 期
Ensayo de fase III para evaluar la función de letrozol continuo vs. letrozol intermitente tras 4 a 6 años de terapia endocrina adyuvante previa en mujeres posmenopáusicas con cáncer de mama temprano con receptores hormonales positivos y ganglios positivos. - SOLEMujeres posmenopáusicas libres de enfermedad tras 4 a 6 años de terapia endocrina adyuvante previa con modulador(es) selectivo(s) del receptor estrogénico (SERM) y/o inhibidores de aromatasa (IA) para cáncer de mama operable con receptores hormonales positivos y ganglios positivos.MedDRA version: 9.1 Level: LLT Classification code 10057654 Term: Breast cancer female
EUCTR2007-001370-88-ESInternational Breast Cancer Study Group (IBCSG)4,800
New Triple Hop Test Quality Assessment Tool | 临床试验